Can I read Bendamustine vs Standard CLL Therapy on EtoBox?

Bendamustine vs Standard CLL Therapy by sharwan5sabharwal is a document available to read on EtoBox.

What is Bendamustine vs Standard CLL Therapy about?

This study evaluated the efficacy and safety of the combination of bendamustine and rituximab (BR) in previously untreated chronic lymphocytic leukemia (CLL) patients. The results showed: 1) The overall response rate was 88.0% with a complete response rate of 23.1% and partial response rate of 64.9%. 2) After a median follow up of 27 months, the median event-free survival was 33.9 months and 90.5% of patients were still alive. 3) Adverse events including grade 3 or 4 infections, neutropenia, thrombocy

Author

sharwan5sabharwal

Language

EN